NCT02337738已完成2 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off
Takeda0 个研究点目标入组 404 人开始时间: 2015年1月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 404
- 主要终点
- Change From Baseline in Mean Daily OFF-time During Treatment Period
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (0.5 mg or 1 mg/day) as an add-on to levodopa in Japanese participants with Parkinson's disease with wearing-off phenomenon.
详细描述
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, phase 2/3 study to evaluate the efficacy and safety of TVP-1012 as an add-on to levodopa in Japanese participants with Parkinson's disease with wearing-off phenomenon.
The study period consisted of a 28-week trial period. The participants who fulfilled the inclusion criteria and did not meeting any of the exclusion criteria were enrolled, and randomized in a 1:1:1 ratio to the 0.5 mg of TVP-1012, the 1 mg of TVP-1012, or the placebo group. In each treatment group, participants received 0.5 mg of TVP-1012, 1 mg of TVP-1012, or placebo once daily in a double-blinded manner.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •In the opinion of the investigator or sub-investigator, the participant is capable of understanding and complying with protocol requirements.
- •The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
- •The participant has a diagnosis of Parkinson's disease according to the diagnostic criteria of the UK Parkinson's Disease Society Brain Bank.
- •The participant has Modified Hoehn & Yahr stage 2 to 4 (in the "Off" state) at the start of the run-in period.
- •The participant has wearing off phenomenon and has been continuously receiving a levodopa combination drug for >= 6 months prior to the start of the run-in period.
- •The participant has been receiving a levodopa combination drug with a stable dose regimen (dosing frequency, at least 3 times a day) since the start of the run-in period.
- •For participants receiving eantacapone concomitantly,the participant has been receiving entacapone with a stable dose regimen from the start of the run-in period.
- •For participants receiving a dopamine agonist, anticholinergic drug, amantadine, droxidopa, istradefylline, or zonisamide concomitantly, the participant has been receiving those drugs with a stable dose regimen since 14 days prior to the start of the run-in period.
- •The participant is an outpatient of either sex aged >= 30 and < 80 years at the time of consent.
- •A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent to 1 month after the last dose of the investigational drug.
- •The participant has completed patient diary for at least 4 of the 7 days preceding the study visit at the end of the run-in period.
- •The participant has mean daily off-time of >= 2.5 hours at the end of the run-in period
排除标准
- •The participant has received any investigational medication within 90 days prior to the start of the run-in period.
- •The participant has received TVP-1012 in the past.
- •The participant is a study site employee, an immediate family member, or in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
- •Participant has donated 400 mL or more of his or her blood volume within 90 days prior to the start of the run-in period.
- •The participant has unstable systemic disease.
- •The participant has severe dyskinesia.
- •The participant has Mini-Mental State Examination (MMSE) score of <= 24 at the start of the run-in period.
- •The participant has known or a history of schizophrenia, major or severe depression, or any other clinically significant psychiatric disease
- •The participant has major depression or severe depression, or any other clinically significant psychiatric disease.
- •The participant has a history of hypersensitivity or allergies to TVP-1012 (including any associated excipients) or selegiline.
- •The participant has a history of clinically significant hypertension or other reactions associated with ingestion of tyramine-rich food (e.g., cheese, lever, herring, yeast, horsebean, banana, beer or wine).
- •The participant has a history or concurrent of drug abuse or alcohol dependence.
- •The participant has received neurosurgical intervention for Parkinson's disease (e.g., pallidotomy, thalamotomy, deep brain stimulation).
- •The participant has received transcranial magnetic stimulation within 6 months prior to the start of the run-in period.
- •The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa within 90 days prior to the start of the run-in period.
- •The participant has received single agent of levodopa, any psychoneurotic agent or antiemetic medication of dopamine antagonist within 14 days prior to the start of the run-in period. However, the participant has been receiving quetiapine or domperidone with a stable dose regimen for >= 14 days prior to the start of the run-in period may be included in the study.
- •The participant is required to take any of the prohibited concomitant medications or treatments.
- •If female, the participant is pregnant or lactating or intending to become pregnant during, or within 1 month after the last administration of study medication in this study; or intending to donate ova during such time period.
- •The participant has clinically significant neurologic, cardiovascular, pulmonary, hepatic (including mild cirrhosis), renal, metabolic, gastrointestinal, urological, endocrine, or hematological disease.
- •The participant has clinically significant or unstable brain or cardiovascular disease, such as:
- •clinically significant arrhythmia or cardiac valvulopathy,
- •heart failure of NYHA Class II or higher,
- •concurrent or a history of ischemic cardiac disease within 6 months prior to the start of the run-in period,
- •concurrent or a history of clinically significant cerebrovascular disease within 6 months prior to the stat of the run-in period,
- •severe hypertension (systolic blood pressure of 180 mmHg or higher, or diastolic blood pressure of 110 mmHg or higher),
- •clinically significant orthostatic hypotension (including those with diastolic pressure decrease of 30 mmHg or more following postural change from supine/sitting position to standing position), or
- •a history of syncope due to hypotension within 2 years prior to the stat of the run-in period.
- •The participant is required surgery or hospitalization for surgery during the study period.
- •Participant has a history of cancer within 5 years prior to the start of the run-in period, except cervix carcinoma in situ which has completely cured.
- •The participant has acquired immunodeficiency syndrome (AIDS) [including human immunodeficiency virus (HIV) carrier], or hepatitis [including viral hepatitis carrier such as hepatitis B surface (HBs) antigen or hepatitis C antibody (HCV) positive]. However, the participant who has a negative result for HCV antigen or HCV-RNA can be included in the study.
- •The participant has laboratory data meeting any of the following at the start of the run-in period:
- •Creatinine >= 2 x upper limit of normal (ULN)
- •Total bilirubin >= 2 x ULN
- •ALT or AST >= 1.5 x ULN
- •ALP >= 3 x ULN
- •The participant has received any of the prohibited concomitant medications or treatments during the run-in period.
- •The participant who, in the opinion of the investigator or sub-investigator, is unsuitable for any other reason.
研究组 & 干预措施
TVP-1012 1mg
Experimental
TVP-1012 1 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
干预措施: TVP-1012 1mg (Drug)
TVP-1012 0.5mg
Experimental
TVP-1012 0.5 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
干预措施: TVP-1012 0.5mg (Drug)
Placebo
Placebo Comparator
One placebo tablet once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in Mean Daily OFF-time During Treatment Period
时间窗: From Baseline to Week 26
Reported change from baseline during treatment period which was calculated as follows: Mean for a total of 21 days, consisting of three separate 7-day periods preceding the visits at Week 6, 14 and 26 of the treatment period - Mean for the 7 days preceding the visit at the end of the run-in period. Off-time refers to times when levodopa is not working well, causing worsening symptoms.
次要结局
- Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Total Score(Baseline and Week 26 (LOCF))
- Change From Baseline to Week 26 (LOCF) in Mean Daily OFF-time(Baseline and Week 26 (LOCF))
- Change From Baseline in MDS-UPDRS Part III Total Score(Baseline and Week 26 (LOCF))
- Change From Baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index Score(Baseline and Week 26 (LOCF))
- Change From Baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) Each Domain Score(Baseline and Week 26 (LOCF))
- Number of Participants With Markedly Abnormal Vital Signs Values(Up to Week 26)
- Number of Participants With TEAE Related to Body Weight (Weight Decreased)(Up to Week 26)
- Number of Participants With TEAE Related to Electrocardiograms (ECG) (Sinus Bradycardia)(Up to Week 26)
- Number of Participants With TEAE Related to Clinical Laboratory Tests(Up to Week 26)
- Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)(Up to Week 26)
研究者
相似试验
已完成
3 期
A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease PatientsParkinson's DiseaseNCT02337725Takeda244
已完成
不适用
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear PalsyProgressive Supranuclear PalsyNCT01049399Noscira SA146
已完成
3 期
Efficacy and Safety Study of XP12B in Women With MenorrhagiaHeavy Menstrual BleedingMenorrhagiaNCT00386308Ferring Pharmaceuticals196
已完成
3 期
Efficacy and Safety of XP12B in Women With MenorrhagiaHeavy Menstrual BleedingMenorrhagiaNCT00401193Ferring Pharmaceuticals304
终止
2 期
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102Diabetic GastroparesisNCT01664637Tranzyme, Inc.120